No Data
Market Still Lacking Some Conviction On Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)
Conn Bay Third Quarter 2024 Report
Express News | Conba Says Q3 Net Profit up 27.2% Y/Y
Zhejiang Conba Pharmaceutical (600572.SH) released its performance for the first three quarters, with a net income of 0.518 billion yuan, a year-on-year decrease of 16.81%.
Zhejiang Conba Pharmaceutical (600572.SH) released the third quarter report for 2024. During the reporting period, the company achieved a revenue of 4...
zhejiang conba pharmaceutical (600572.SH): net income of 0.518 billion yuan in the first three quarters, a year-on-year decrease of 16.81%.
Gelonghui October 29th | Zhejiang Conba Pharmaceutical (600572.SH) released the third quarter report, with revenue in the first three quarters of 4.913 billion yuan, a decrease of 5.23% year-on-year, net income of 0.518 billion yuan, a decrease of 16.81% year-on-year, non-net profit of 0.424 billion yuan, a decrease of 16.84% year-on-year, and basic earnings per share of 0.205 yuan.
Zhejiang Conba Pharmaceutical (600572.SH): ZY13 extract and tablets have obtained the drug clinical trial approval letter.
On October 21st, Kangenbei (600572.SH) announced that the company has received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration for the ZY13 extract and tablets. The ZY13 tablets for clinical trials applied by the company are indicated for age-related macular degeneration caused by kidney yin deficiency and hyperactivity of fire, administered orally, and classified as a new traditional chinese medicine category 1.2 drug. The most appropriate dosage will be confirmed after the clinical trial ends. The pharmacological experiments conducted on this product have shown that the ZY13 extract has the effect of inhibiting choroidal neovascularization. As of now, the company has invested in this product.
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The BusinessNo Data
No Data
